Newsletter of i+ Solutions

[Guest guest]

Pl see the left margin for their forthcoming trainings and courses.

Do read how a pharma giant has finally come forward to offer its services for the widely prevalent disease of developing countries - malaria.

Vijay

-------------------------------------------------------------------------------------------------------------------------

..

.

SCM Discussion Platform Newsletter

January 2010

Newsletter 26

In this issue:

GlaxoKline announces `open innovation' strategy

UNITAID patent pool for HIV/AIDS medicines approved

New PEPFAR 5-year strategy

i+solutions Trainings 2010 (The Netherlands)

Managing Drug Supply in Low and Middle Income Countries

31May-11June 2010(French edition)

18-29 October 2010 (English edition)

ARV Procurement and Supply Management

10-21 May 2010 (English edition)

6-17 December 2010 (French edition)

Monitoring and Evaluation of Procurement and Supply Management

7-12 February 2010 (English edition)

21-26 February 2010 (French edition)

Procurement and Supply Management of Artemisinin-based Combination Therapies

17-26 March 2010 (French edition)

21-30 July 2010 (English edition)

Procurement and Quantification Management of Medicines and Medical Supplies

11-16 April 2010 (English edition)

26September-01 October 2010 (French edition)

Procurement and Supply Management of Essential Laboratory Supplies for HIV/AIDS, Malaria and TB

17-26 November 2010 (English edition)

Executive Seminar – Pharmaceutical Supply Chain Management

27June – 2 July 2010 (English edition)

AA4A Trainings 2010 (South Africa)

Warehouse Operations Management (English)

22 February – 19 March 2010

03 May – 28 May 2010

16 August – 10 September 2010

04 October – 29 October 2010

08 November – 03 December 2010

Supply Chain Management of HIV/AIDS Medicines and Supplies (English)

12 April – 23 April 2010

25 October – 05 November 2010

Conferences

XVIII International AIDS Conference (AIDS 2010), Vienna, Austria

18 – 23 July 2010

Contact Us

platform@...

http://www.iplussolutions.org/platform

GlaxoKline announces `open innovation' strategy

On 20th January 2010, GlaxoKline revealed that it will open up its database containing thousands of potential anti-malaria compounds to the world's scientists. This is part of a series of new initiatives on the company's approach to diseases that disproportionately affect the world's poorest people. 13,500 compounds that have potential to act against the parasite that causes malaria will be made freely available.

GlaxoKline also announced the establishment of an `Open Lab' for scientific innovation for neglected tropical diseases. The `Open Lab', to be based at the Tres Cantos Campus in Spain, will enable scientists to pursue their own projects while tapping into GlaxoKline's expertise, knowledge and infrastructure, as part of an integrated drug discovery team. An initial seed investment of US $8 million will be made by GlaxoKline towards funding research and facilitating better knowledge sharing.

Click here to read more.

UNITAID patent pool for HIV/AIDS medicines approved

A Patent Pool for AIDS medicines, approved by UNITAID's Executive Board in mid-December 2009, is scheduled to start operating in mid-2010. UNITAID strives to make newer medicines available to large group of patients, in patient-adapted form and at lower prices, by creating a common space for patent holders to license their technology in exchange for royalties. The resulting competition will further bring down the prices of vital new medicines, giving hope to millions of patients in need of them. Providing start-up funds of up to US $ 4 million over 2010, UNITAID expects savings to exceed one billion US dollars a year.

Click here to read more.

New PEPFAR 5-year strategy

In PEPFAR's new 5-year strategy, unveiled on World AIDS Day 2009, a move from emergency response towards sustainable country programs will be promoted. Other goals include strengthening partner government capacity to lead the response to the HIV/AIDS epidemic; expansion of prevention, care and treatment in concentrated and generalized epidemics; impact maximization through integration of HIV/AIDS programs with broader health and development programs; and investment in innovation and operations research to evaluate impact, improve service delivery and maximize outcomes.

Click here to read more.